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Abstract 1 
Background: Timely diagnosis of acute exacerbations of COPD (AECOPD) is challenging 2 
as it depends on patients’ reports. AECOPD are characterised by increased airway 3 
obstruction, mucus and air trapping, which results in changes in lung acoustics. Thus, 4 
adventitious respiratory sounds (ARS) may be useful to detect/monitor AECOPD. 5 
Objective: To evaluate computerised ARS changes during AECOPD. 6 
Methods: 25 non-hospitalised patients with AECOPD (16♂, 70[62.5-77.0]yrs, FEV1 59[31.5-7 
73.0]%predicted) and 34 healthy volunteers (17♂, 63.5[57.7-72.3]yrs, FEV1 103.0[88.8-8 
125.3]%predicted) were enrolled. ARS at anterior and posterior right and left chest were 9 
recorded at hospital presentation (T1), 15 days (T2) and 45 days (T3) after hospital 10 
presentation from patients with AECOPD and only once from healthy participants. A 11 
subsample of 9 patients (7♂; 66[60.0-76.0]yrs; FEV1 62[26.5-74.0]%predicted) was also 12 
included to study ARS pre-AECOPD (T0). Number of crackles and wheeze occupation rate 13 
(%Wh) were processed using validated algorithms. 14 
Results: During AECOPD, patients presented more inspiratory crackles at T1 than T3 15 
(p=0.013) and more inspiratory %Wh at T1 than T2 (p=0.006), at posterior chest. Patients 16 
with stable COPD presented more inspiratory crackles (p=0.012), at posterior chest, and 17 
more expiratory %Wh, both at anterior (p<0.001) and posterior (p=0.001) chest, than healthy 18 
participants. No differences were observed for the remaining ARS parameters or 19 
subsamples (p>0.05). 20 
Conclusions: Inspiratory crackles seem to persist until 15 days post exacerbation whilst 21 
inspiratory %Wh decreased after this period. ARS seem to be sensitive to monitor AECOPD. 22 
This information may allow advances in monitoring the recovery time of patients with 23 
AECOPD across all clinical and non-clinical settings. 24 
Key-Words: chronic obstructive pulmonary disease; acute exacerbations; crackles; 25 
wheezes; computerised respiratory sounds 26 
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Introduction 1 
Chronic Obstructive Pulmonary Disease (COPD) is a progressive respiratory disease 2 
frequently punctuated by acute exacerbations (AECOPD) [1], i.e., “acute worsening of 3 
respiratory symptoms that result in additional therapy” [2]. These events account for half of 4 
the total respiratory admissions for COPD [3] and are closely related with increases in 5 
healthcare costs (AECOPD related costs vary approximately from $88 to $7.757 per 6 
exacerbation worldwide) [4]. Furthermore, AECOPD are responsible for accelerating lung 7 
function decline, decrease quality of life and increase mortality [5]. 8 
The early identification and timely management of AECOPD has been shown to reduce 9 
hospital admissions and recovery time, while improving quality of life [6]. Nevertheless, most 10 
exacerbations are still not timely treated as the diagnosis/monitoring relies exclusively on 11 
patients’ reports of symptoms worsening [2]. Such reports require patients’ collaboration and 12 
judgment, which are frequently affected by their pronounced dyspnoea and anxiety 13 
associated with these events [7, 8]. 14 
Physiologically, AECOPD are characterised by an increase in airway inflammation and 15 
obstruction, abnormal bronchial mucus production and marked air trapping [2], which results 16 
in changes in lung acoustics. As respiratory sounds are directly related to the movement of 17 
air within the tracheobronchial tree [9], the changes in respiratory mechanics related with 18 
AECOPD may be primarily detected by changes in respiratory sounds, namely adventitious 19 
respiratory sounds (ARS, crackles and wheezes). Recent studies have shown respiratory 20 
sounds ability to differentiate between groups of patients with stable and exacerbated COPD 21 
[10] and to characterise AECOPD into two phenotypes, based on computerised analysis 22 
[11]. 23 
Nevertheless, there is little information available on the time course of respiratory sounds 24 
changes during recovery from AECOPD, within the same group of patients. This information 25 
may advance the monitoring of patients with COPD across all clinical and non-clinical 26 
settings, as respiratory sounds are non-invasive, population-specific and nearly universally 27 
available by simple means [12]. Additionally, improved knowledge on ARS behaviour 28 
preceding, during and after an exacerbation may aid to standardise and optimise the length 29 
of treatment, and to plan appropriate follow-up and clinical studies involving AECOPD. 30 
This study aimed to evaluate ARS changes during the course of AECOPD. A secondary aim 31 
was to explore prospectively the influence of exacerbations in ARS in a subsample of 32 
patients with stable COPD followed by an AECOPD. 33 
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Material and methods 1 
Study design and participants 2 
A longitudinal observational study was conducted in non-hospitalised patients with AECOPD 3 
recruited from the urgent care of a Central hospital between January 2016 and February 4 
2017. Inclusion criteria were diagnosis of AECOPD according to the Global Initiative for 5 
Chronic Obstructive Lung Disease (GOLD) criteria [2]. A subsample of stable patients with 6 
COPD was recruited from routine pulmonology appointments of a Central hospital and asked 7 
to contact the researchers if an episode of exacerbation requiring hospital visit occurred. 8 
Patients were included if they were diagnosed with COPD according to the GOLD criteria 9 
and were clinically stable for 1 month prior to the study (no hospital admissions, 10 
exacerbations or changes in medication for the respiratory system) [2]. Exclusion criteria for 11 
both samples were hospitalisation or presence of severe co-existing respiratory, 12 
neurological, cardiac, musculoskeletal (e.g., kyphoscoliosis), or psychiatric impairments. 13 
Eligible patients were identified by clinicians and contacted by the researchers, who 14 
explained the purpose of the study and asked about their willingness to participate. When 15 
subjects agreed to participate, an appointment with the researchers was scheduled. 16 
A group of healthy non-smokers, matched for gender, age and body mass index (BMI), were 17 
also recruited to serve as control, as currently there are no established reference values for 18 
ARS [13]. Healthy non-smokers were recruited from the university campus and surrounding 19 
community and excluded if they presented one or more of the following conditions: acute 20 
(within the past month) or chronic respiratory disease, cardiac disease, musculoskeletal or 21 
signs of psychiatric impairments. 22 
Approval for this study was obtained from the ethics committee of the Central Hospital 23 
(13NOV’1514:40065682) and of the University of (omitted for blinded purposes) (8/2015) 24 
and from the National Data Protection Committee (8828/2016). Written informed consent 25 
was obtained before data collection. 26 
 27 
Sample size 28 
A sample size estimation with 95% power at 5% significance determined that a significant 29 
difference in the inspiratory mean number of crackles obtained through repeated measures 30 
from patients with COPD at exacerbated (2.97±1.98) and stable (1.20±0.80) phases of their 31 
disease would be detected with a minimum of 23 participants [10]. A high statistical power 32 
was chosen due to the great amount of inter and intra subject variability presented by ARS 33 
[14, 15], which could potentially cause type II errors if the study was underpowered [16]. In 34 
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health-related longitudinal studies, dropout rates are of approximately 20 to 45% [17, 18] 1 
thus, 36 participants with AECOPD were aimed to be recruited. Sample size estimation was 2 
performed using the G*Power 3.1 software (University Düsseldorf, Germany). 3 
 4 
Data collection 5 
Participants with AECOPD recruited from the urgent care were asked to attend to 3 6 
assessment sessions: at the exacerbation onset (T1 – 24 to 48 hours of the hospital visit), 7 
15 days (T2 – following exacerbation) [19, 20] and 45 days after the hospital visit (T3 – at 8 
stability post exacerbation). The subsample of patients recruited from routine pulmonology 9 
appointments were asked to attend to 4 assessment sessions: 24 to 48 hours after the 10 
pulmonology routine appointment (T0 – at stability pre exacerbation), at the exacerbation 11 
onset (T1 – 24 to 48 hours of the hospital visit), 15 days (T2 – following exacerbation) [19, 12 
20] and 45 days after the hospital visit (T3 – at stability post exacerbation). Data from 13 
healthy non-smokers was only collected once (T0) (Figure 1). Data collection occurred at the 14 
urgent care, in the facilities of the University of (omitted for blinded purposes) or at patients’ 15 
home.  16 
 17 
 18 
Figure 1 – Time points of data collection. 19 
Sociodemographic (age, gender), anthropometric (height, weight and BMI) and general 20 
clinical data (smoking habits, number of exacerbations in the past year, medication and 21 
dyspnoea) were first collected. Dyspnoea was assessed with the modified British Medical 22 
Research Council questionnaire [21]. The questionnaire comprises five grades in a scale 23 
from 0 to 4, with higher grades indicating greater perceived dyspnoea. Then, computerised 24 
respiratory sounds (recorded as described below) and lung function, assessed with a 25 
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portable spirometer (MicroLab 3535, CareFusion, Kent, UK) according to standardised 1 
guidelines were collected [22]. Respiratory sounds were collected in all data collection 2 
moments and spirometry was also performed at T3, during the stable phase, post 3 
exacerbation. 4 
All assessments were performed by a physiotherapist following the described standardised 5 
order. 6 
Respiratory sound recordings  7 
Respiratory sound recordings followed computerised respiratory sound analysis guidelines 8 
for short-term acquisitions [23] (i.e., participants were in a seated-upright position, wearing a 9 
nose clip and were asked to breathe deeper than normal through the mouth). Recordings 10 
were performed simultaneously at 7 anatomic locations (trachea and right and left anterior, 11 
lateral, and posterior chest). The system for respiratory sound recordings included eight air-12 
coupled electret microphones with 20-20kHz frequency bandwidth (C 417 PP, AKG Acoustics 13 
GmbH, Vienna, Austria) [24]. a multi-channel audio interface (AudioBox 1818 VSL, 14 
PreSonus, Florida, USA), and a laptop computer running LungSounds@UA software [25]. 15 
Seven microphones, mounted in capsules made of Teflon [26, 27], were attached on the 16 
participant’s skin with double-faced adhesive tapes (Double Stick Discs, 3M Littmann, 17 
Cheshire, UK). The eighth microphone was placed close to the patient to record background 18 
noise. The analog sound signals acquired were amplified and converted to digital by the 19 
audio interface with a 24-bit resolution and a sampling rate of 44.1 kHz. Each data 20 
acquisition session lasted for 20-s [28] and the recorded data were later converted to WAV 21 
format.  22 
Signal processing 23 
All sound files were analysed using automatic algorithms implemented in Matlab R2009a 24 
(MathWorks, Natick, Massachusetts).  25 
Breathing cycles were semi-automatically detected using the algorithm developed by Huq 26 
and Moussavi (95.5% sensitivity and 95.6% specificity) [29]. Crackles were detected using a 27 
validated algorithm based on the combination of fractal dimension and box filtering 28 
techniques [30]. Wheezes were detected using an algorithm based on time-frequency 29 
analysis [31]. The mean number of crackles (total, fine and coarse) and wheeze occupation 30 
rate (%Wh – total, monophonic and polyphonic), per breathing phase (inspiration and 31 
expiration) and per chest location was extracted. Normal respiratory sounds were also 32 
analysed but were only slightly louder than the superimposed background sound so these 33 
data were excluded from further analyses (please see supplementary material 1). The 34 
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average spectra of normal respiratory sounds at trachea, anterior and posterior chest can be 1 
found in the supplementary material 1 and a detailed description of the signal processing is 2 
provided elsewhere [32]. Lateral locations were also excluded from the analysis, as previous 3 
literature as shown that this anatomical location presents a great number of artefacts and is 4 
poorly reliable [15]. All analyses were checked by two respiratory experts to ensure the 5 
quality of the sound recordings.  6 
 7 
Statistical Analysis 8 
All statistical analyses were performed using IBM SPSS Statistics version 24.0 (IBM 9 
Corporation, Armonk, NY, USA) and plots created using GraphPad Prism version 5.01 10 
(GraphPad Software, Inc., La Jolla, CA, USA). The level of significance was set at 0.05. 11 
Descriptive statistics were used to describe the sample. Characteristics were compared 12 
between healthy non-smokers and patients with COPD at stable phases (T3) using 13 
independent t-tests for normally distributed data (i.e., BMI), Mann-Whitney U-tests for non-14 
normally distributed data (i.e., age, lung function, packs-year) and ordinal data (i.e., mMRC), 15 
and Chi-square tests for categorical data (i.e., gender, smoking status, exacerbations/year 16 
and GOLD stages). 17 
 18 
Computerised ARS data were explored for each of the five analysed locations; however, no 19 
significant differences were found between right and left chest of the same region (i.e., 20 
anterior, lateral or posterior), thus, to simplify the interpretability of the findings, data from 21 
right and left were pooled for each chest region [32]. Then, the number of participants with 22 
crackles and wheezes in each chest region was calculated and the Cochran test with 23 
Bonferroni corrections was used to compare number of participants presenting crackles and 24 
wheezes among T1, T2 and T3. Fisher’s exact test was used to investigate differences 25 
between healthy non-smokers and patients with COPD at stable phases (T3) on the number 26 
of participants presenting crackles and wheezes. Comparisons of number of crackles and 27 
%Wh among T1, T2 and T3 in patients with COPD were performed with the Friedman test, 28 
and multiple comparisons with the Wilcoxon sign-rank test. Multiple comparisons were 29 
corrected for number of comparisons using Bonferroni corrections. Comparisons between 30 
healthy non-smokers and patients with COPD at stable phases regarding mean number of 31 
crackles and %Wh was performed with Mann–Whitney U test. When statistically significant 32 
differences were found for the number of crackles or %Wh, a comparison of the type of 33 
crackles or wheezes was also performed. 34 
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An additional analysis, similar to the described previously for patients recruited at the onset 1 
of the AECOPD, was conducted with the subsample of patients presenting data collected 2 
prior to the exacerbation. 3 
 4 
Results 5 
 6 
Participants 7 
Seventy-four non-hospitalised patients with AECOPD were referred for possible inclusion in 8 
the study. Of these, 34 patients refereed with AECOPD were excluded because at T1 they 9 
had pulmonary function test not compatible with a diagnosis of COPD (n=22), did not meet 10 
the definition for AECOPD (n=1), presented lung neoplasia (n=2), severe heart failure (n=1), 11 
were unable to comply with data collection (n=3), or declined to participate in the study 12 
(n=5). Fifteen patients were further excluded from the analysis because failed to complete all 13 
time points of data collection (i.e., T1, T2 and T3) (n=6) and their respiratory sounds 14 
(collected at the urgent care) had a significant amount of background noise hindering the 15 
use of the algorithms described in the Signal processing section (n=9). Thirty-four healthy 16 
non-smokers were also contacted and invited to participate. Thus, twenty-five participants 17 
with AECOPD (16 males; 70 [62.5-77.0] years old; FEV1 59 [31.5-73.0]% predicted) and 18 
thirty-four healthy non-smokers (17 male; 63.5 [57.7-72.3] years old; FEV1 103.0 [88.8-19 
125.3]% predicted) were enrolled in the study. Participants’ characteristics are summarised 20 
in Table 1. 21 
 22 
Table 1. Sample characterization. 23 
Characteristics Patients with  
AECOPD 
(n=25) 
Healthy 
non-smokers 
(n=34) 
p-value 
Age, years 70 [62.5-77.0] 63.5 [57.7-72.3] 0.061 
Gender (male), n(%) 16 (47.1) 17 (68.0) 0.090 
BMI, kg/m2, mean±SD 26.7±4.9 27.4±4.7 0.568 
Smoking status, n(%) 
Current 
Former 
Never 
 
4 (16.0) 
11 (44.0) 
10 (40.0) 
 
- 
6 (17.6) 
28 (82.4) 
0.002* 
Packs/year  30.0 [15.0-70.0] 6.5 [1.8-18.8] 0.010* 
Exacerbations/year, n(%)   <0.001* 
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0 
1 
≥2 
5 (20) 
5 (20) 
15 (60) 
34 (100) 
- 
- 
FEV1, L 1.2 [0.8-1.7] 2.6 [2.1-3.0] <0.001* 
FEV1, %predicted 59 [31.5-73.0] 103.0 [88.8-125.3] <0.001* 
FEV1/FVC, % 52 [40.0-62.0] 83 [79.5-88.3] <0.001* 
GOLD stages, n(%)    
A 4 (6.8) -  
B 3 (5.1) -  
C 5 (8.5) -  
D 13 (22.0) -  
Medication use, n(%) Stability AECOPD (extra)   
Antibiotics 1 (4) 15 (60) -  
Bronchodilators   -  
Beta-adrenergic agonists 7 (28) 0 (0) 0  
Cholinergic antagonists 15 (60) 3 (12) 0  
Anti-inflammatory 4 (16) 1 (4) 0  
Xanthines 8 (32) 0 0  
Associations of bronchodilators 
with cholinergic antagonists 
17 (68) 5 (20) 0  
Expectorants 4 (16) 6 (24) 0  
mMRC 1 [0.5-2.0] 0.0 [0.0-1.0] <0.001* 
*p<0.05 1 
Values are presented as median [interquartile range], unless otherwise stated. 2 
Legend: BMI, body mass index; FEV1, forced expiratory volume in one second (at stability); FVC, forced vital 3 
capacity (at stability); GOLD, Global Initiative for Chronic Obstructive Lung Disease; mMRC, Modiﬁed British 4 
Medical Research Council questionnaire; SD, standard deviation. 5 
 6 
A subsample of 9 participants with stable COPD a priori was also included and followed up 7 
until an AECOPD occurred and during its recovery. This sub-group of participants (7 males; 8 
66 [60.0-76.0] years old; FEV1 62 [26.5-74.0]% predicted) was slightly overweight (27.9±4.46 9 
Kg/m2), presented a median number of packs/year of 21.2 [10.0-30.0] and were mainly 10 
former smokers (n=5; 55.6%; current smokers: n=2; 22.2%; never smokers: n=2; 22.2%). 11 
Most participants were classified as being in a stage D of the GOLD classification (n=5; 12 
55.6%; GOLD B: n=2; 22.2%; GOLD C: n=2; 22.2%), presented more than 2 AECOPD in the 13 
past year (n=6; 66.7%; 1 AECOPD: n=2; 22.2%; 0 AECOPD: n=1; 11.1%) and were treated 14 
for their AECOPD with antibiotics (n=5; 56%), cholinergic antagonist bronchodilators (n=2; 15 
22%), anti-inflammatory bronchodilators (n=1; 11%) and expectorants (n=3; 33%). Patients 16 
presented a median mMRC of 2 [1-3]. Median time to exacerbation was 23 [18-146] days. 17 
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Figure 2 – Number of inspiratory and expiratory crackles in healthy participants and participants with COPD (T1, T2, T3) at 
A) trachea, B) anterior and C) posterior chest regions. 
* significantly different from T3. 
Computerised Respiratory Sounds 1 
 2 
Crackles 3 
Significant differences were found in the total number of inspiratory (p=0.008) and coarse 4 
(p=0.003) crackles within patients with AECOPD at T1, T2 and T3 at the posterior chest. 5 
Patients presented significantly more inspiratory (p=0.013) and coarse (p=0.013) crackles at 6 
T1 than at T3. Figure 2 presents the number of crackles at each chest region in healthy 7 
participants and patients with AECOPD. A detailed characterisation of crackles can be found 8 
in the supplementary material 2. 9 
 10 
Patients with stable COPD presented significantly more inspiratory crackles (p=0.012), both 11 
fine (p=0.003) and coarse (p=0.013) crackles, at the posterior chest than healthy 12 
participants. No significant differences were found regarding the remaining variables, 13 
locations or respiratory phases (p>0.05). 14 
 15 
Wheezes 16 
Significant differences were found in the inspiratory %Wh (p=0.019) and inspiratory 17 
monophonic %Wh (p=0.012), within patients with AECOPD at T1, T2 and T3 at posterior 18 
chest. Namely, patients presented significantly more inspiratory %Wh (p=0.006) and 19 
monophonic %Wh (p=0.045) at T1 than at T2. A higher number of patients presenting 20 
inspiratory wheezes and monophonic wheezes were found at T1 than at T2 at trachea 21 
(p=0.037) and anterior chest region (p=0.014). The number of patients with expiratory 22 
monophonic wheezes was also higher at T1 than at T3 at the anterior chest (p=0.029). No 23 
significant differences were found regarding the remaining variables, locations and 24 
respiratory phases (p>0.05). Figure 3 presents the %Wh at each chest region in healthy 25 
participants and patients with AECOPD. A detailed characterisation of wheezes can be 26 
found in the supplementary material 3. 27 
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Figure 3  –Inspiratory and expiratory wheeze occupation rate in healthy participants and participants with COPD (T1, T2, 
T3) at A) trachea, B) anterior and C) posterior chest regions. 
* significantly different from T3. 
† significantly different from T2. 
 
 
 
 1 
 2 
Patients with stable COPD presented significantly more expiratory and monophonic %Wh, 3 
both at anterior (total %Wh: p<0.001; monophonic %Wh: p=0.007) and posterior (total %Wh: 4 
p=0.001; monophonic %Wh: p<0.001) chest regions than healthy participants. No 5 
differences were found regarding the number of healthy participants and stable patients with 6 
wheezes (p>0.05). 7 
 8 
Sub-analysis 9 
No differences were found among the four-time points of data collection for inspiratory and 10 
expiratory crackles and wheezes at all anatomical locations (p>0.05), in the subsample of 11 
patients with stable COPD a priori. A detailed characterisation of the respiratory sounds of 12 
this subsample can be found in the supporting information 4 and 5. 13 
 14 
Discussion 15 
The main findings of this study were that inspiratory crackles and wheezes change 16 
significantly during the course of AECOPD and patients with stable COPD presented 17 
significantly more inspiratory crackles and expiratory wheezes than healthy peers.  18 
Differences in ARS found during the course of AECOPD and between stable patients with 19 
COPD and healthy peers were mainly observed at posterior and more peripheral chest 20 
locations, both for crackles and wheezes. In previous studies, the posterior region has been 21 
indicated as the most reliable and valid chest location for auscultation in patients with COPD 22 
[14, 15]. These findings, added to physiological and epidemiological data showing that 23 
COPD is primarily targeted by smaller airway and/or alveolar abnormalities [2] and that 24 
approximately 70-80% of AECOPD are due to infections, especially of the small airways 25 
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[33], might lead us to confidently identify the posterior chest region as the preferred location 1 
of auscultation to monitor patients with COPD.  2 
Coarse crackles and monophonic wheezes during inspiration were the respiratory sounds 3 
parameters presenting significant degrees of change. Previous research, conducted in 4 
independent samples of stable and exacerbated patients with COPD, has shown equivalent 5 
results for the number of coarse crackles [10], despite acknowledging that respiratory tract 6 
infections, the main cause of AECOPD, are mainly characterised by fine crackles. Such 7 
results have been attributed to the frequency response of stethoscopes used which might be 8 
cutting high frequencies of interest, and consequently affect fine crackles detection [34]. 9 
Thus, a deeper understanding of this matter is yet needed. Respiratory tract infections define 10 
a wide range of infectious diseases, including pneumonia, acute bronchitis, AECOPD and 11 
acute infective exacerbations of asthma [35]. Pneumonia is the respiratory infection most 12 
studied for ARS [36]. It should be emphasised that AECOPD and pneumonia differ greatly in 13 
their pathophysiology [2, 36]. AECOPD is characterised by an increase in airway 14 
inflammation and obstruction, abnormal bronchial mucus and marked air trapping [2], whilst 15 
pneumonia usually presents lung consolidation and a filling of the alveolar air spaces with 16 
exudate, inflammatory cells, and fibrin [36]. Accordingly, AECOPD are more prompt to 17 
develop hypersecretions than pneumonia and thus, generate more coarse crackles, which 18 
“indicates intermittent airway opening related to secretions”, than fine crackles that are 19 
“unrelated to secretions” [12].  20 
Contrary to what has been reported in previous literature [10], only inspiratory wheezes 21 
presented significant changes during the course of AECOPD. Compared to crackles, 22 
wheezes usually present higher inter subject variability [14] and, in patients with more severe 23 
airway obstruction, expiratory wheezes have been indicated as a poorly reliable parameter, 24 
as they are strongly influenced by air-flow and respiratory manoeuvres [15]. Because 25 
previous research has been conducted using independent samples of patients with stable 26 
and AECOPD, variability might be increased, explaining the differences found. Also, 27 
previous studies have included mainly mild to moderate patients with COPD [10, 37], whilst 28 
our sample included mostly severe patients, where inspiratory wheezes might be more 29 
representative. 30 
Considering the changes in ARS during the course of AECOPD, %Wh, specifically 31 
monophonic, significantly decreased after 15 days of treatment (i.e., approximate time 32 
needed to resolve an AECOPD [19]), whilst crackles, specifically coarse crackles, only 33 
decreased significantly after 45 days post-exacerbation. Previous studies conducted during 34 
an AECOPD have shown an improvement in air-flow limitation (assessed by FEV1 and peak 35 
13 
 
expiratory flow - PEF) approximately 15-days post exacerbation [7, 19]. Knowing that %Wh 1 
is highly associated with the degree of bronchial obstruction [38, 39], this was an expected 2 
result and enhances the role of wheezes auscultation to monitor AECOPD. Crackles are 3 
more related to changes (i.e., inflammation and/or infection) in more peripheral airways 4 
which usually take longer to resolve [40, 41]. 5 
No differences were observed in the subsample of patients with stable COPD studied a priori 6 
and during AECOPD across any time points. Thus, it was not possible to demonstrate if ARS 7 
recovered to baseline characteristics after an exacerbation, or if AECOPD have a cumulative 8 
effect in ARS similar to other outcomes, such as muscle strength and lung function [5]. It is 9 
known that ARS present high inter and intra subject variability [14] and thus, the sample size 10 
included in this sub-analysis might have been insufficient to detect significant changes. 11 
Nevertheless, if ARS are to be used clinically, knowing their evolution before and after 12 
exacerbations is essential to better interpret and manage treatment. This sub-analysis was 13 
therefore a needed first step towards ARS use in the monitoring of AECOPD and can be 14 
used as a pilot study to compute sample sizes in future studies (data are in supporting 15 
information 4 and 5). 16 
Patients with COPD presented significantly more inspiratory crackles and expiratory 17 
wheezes than healthy peers. It is known that COPD is mainly characterized by inspiratory 18 
and coarse crackles and expiratory wheezes [42], when compared with other chronic 19 
diseases, such as fibrosis, asthma, pneumonia, bronchiectasis and heart failure. Thus, this 20 
was an expected result. However, few studies have compared ARS in healthy people and 21 
patients with COPD, even though the presence of ARS has been recognized in healthy 22 
people [13]. Although differences in ARS were found between patients with COPD and 23 
healthy people the number of people with ARS in both groups was not significantly different. 24 
Therefore, our results further enhance the recommendation of not using the presence of 25 
ARS as an indicator of pathology [15], but instead investigate ARS characteristics (i.e., 26 
number, type, position in the respiratory cycle) and place it together with other clinical 27 
findings. 28 
Comparing to previous studies, a small number of crackles and low %Wh were found in 29 
patients with COPD (median no. of crackles per respiratory phase between 0.3 in stable 30 
patients to 0.6 in AECOPD; median %Wh of approximately 0) and healthy people (median 31 
no. of crackles and %Wh of approximately 0). Studies have been indicating a mean number 32 
of crackles between 0.8 to 5 per respiratory phase and a mean %Wh of 0.79% to 33 
approximately 10% in patients with COPD [10, 42, 43] and approximately 1.5 crackles and 34 
35% %Wh in healthy people [32]. Reasons for these differences might be explained by the 35 
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different protocols used to collect and analyse ARS. In this study, ARS were collected using 1 
AKG air-coupled electret microphones (response rate 20-20000Hz) mounted in capsules 2 
made of Teflon to minimize noise and increase sound transmission [26, 27]. Additionally, all 3 
participants, independently of having ARS or not, were included in the analysis to potentiate 4 
the comprehensiveness and generalization of our findings. Previous studies have used 5 
sensors with different frequency responses (e.g., 40-15000 [32]; 50-1800Hz; 4-20000Hz; 65-6 
20000Hz [42]), diverse set ups of data collection (e.g., electret microphones imbedded in a 7 
soft foam mat and electret condenser microphones connected to the diaphragm or main tube 8 
of conventional stethoscopes [10, 42, 43]) and analysis (have only included in their analysis 9 
people presenting ARS [32]). Such variety of procedures may produce recordings of different 10 
quality and range of sound spectrum, influencing the results achieved and thus impairing 11 
comparisons among studies.  12 
Limitations 13 
This study has some limitations that need to be acknowledged. Firstly, treatment of 14 
exacerbations during this study was not standardised, but rather prescribed according to the 15 
physician best judgment and clinical indication. Although for the purpose of this study the 16 
effects of therapies used were not of interest, it has to be acknowledge that different 17 
combination of drugs might have influenced the recovery times and outcomes of individual 18 
patients. Secondly, flows and/or volumes were not controlled during ARS recordings, which 19 
might have affected the results, since ARS characteristics depend on the rate and volume of 20 
the respiratory manoeuvres [44]. However, patients with AECOPD often present severe 21 
dyspnoea and anxiety [7, 8] which causes the use of a mouthpiece or facemask (necessary 22 
to assess flows and/or volumes) to be highly uncomfortable or even not tolerated. 23 
Furthermore, the primary purpose of this study was to assess computerised ARS utility in a 24 
community-based clinical setting, where control of airflow is often not practical. Thirdly, the 25 
complex set up used to record ARS may be perceived as a limitation to the use of 26 
computerised respiratory sounds in the clinical practice. Future research should focus in 27 
developing technologies for acquiring high quality data at bedside with minimal setup. 28 
Finally, although statistically significant differences were found for inspiratory number of 29 
crackles and %Wh at posterior regions, the absolute differences among data collection times 30 
were small and possibly not detected by health professionals with standard auscultation. 31 
Thus, it is imperative that future studies explore the minimal clinical important difference of 32 
ARS to enhance the clinical meaning of this measure and potentiate the development and 33 
implementation of friendly used computerised auscultation systems that can be translated 34 
into clinical practice. 35 
 36 
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Conclusion 1 
Inspiratory crackles and wheezes changed significantly during the course of AECOPD, and 2 
patients with stable COPD presented significantly more inspiratory crackles and expiratory 3 
wheezes than healthy peers. Inspiratory crackles seem to persist until 15 days after the 4 
exacerbations (i.e., approximate time needed to resolve AECOPD) whilst inspiratory %Wh 5 
significantly decreased after this period. Crackles and wheezes seem to be sensitive to 6 
monitor the course of AECOPD. This information may allow further advances in the 7 
monitoring of patients with COPD across all clinical and non-clinical settings, as respiratory 8 
sounds are non-invasive, population-specific and nearly universally available by simple 9 
means. Further studies with larger samples and including data collected before the AECOPD 10 
are needed to confirm these findings. 11 
  12 
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